Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Stability of Memantine in an Extemporaneously Prepared Oral Liquid

Author(s):  Yamreudeewong Weeranuj, Teixeira M Glaucia, Mayer Gabriele E

Issue:  Jul/Aug 2006 - Sterile Preparations
View All Articles in Issue

Page(s):  316-317

Stability of Memantine in an Extemporaneously Prepared Oral Liquid Page 1
Stability of Memantine in an Extemporaneously Prepared Oral Liquid Page 2

Download in electronic PDF format for $65

Abstract:  Memantine, a N-methyl-D-aspartate receptor antagonist, was recently approved by the United States Food and Drug Administration for the palliative treatment of moderate to severe Alzheimer’s disease. Its suggested mechanism of action in the treatment of Alzheimer’s disease is binding to N-methyl-D-aspartate receptors, which results in inhibition of glutamate activity. Glutamate has been reported to contribute to the pathogenesis of Alzheimer’s disease by overstimulating the N-methyl-D-aspartate receptors, resulting in brain cell damage. The stability of memantine in an extemporaneously prepared oral liquid was studied. An aqueous liquid formulation was prepared by reconstituting memantine powder from triturated tablets with deionized water. The expected memantine concentration was 0.166 mg/mL. The memantine liquid was transferred into two glass prescription bottles; one was stored at room temperature (25°C), and the other in the refrigerator (2°C). Aliquots from each bottle were analyzed in quadruplicate on days 0, 1, 2, 3, 4, 7, 14, and 28 by using a gas chromatograph-mass spectrometer. The results of this study indicate that the extemporaneously prepared memantine oral liquid was stable for up to 7 days at room temperature and up to 28 days in the refrigerator.

Related Keywords: Weeranuj Yamreudeewong, PharmD, M. Glaucia Teixeira, PhD, Gabriele E. Mayer, PhD, memantine, N methyl D aspartate receptor antagonist, NMDA blocker, Alzheimer's disease, dementia, liquid formulation, stability


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
Stability of Memantine in an Extemporaneously Prepared Oral Liquid
Yamreudeewong Weeranuj
, Teixeira M Glaucia, Mayer Gabriele E
Jul/Aug 2006
Pg. 316-317

Stability of Clopidogrel in Three Extemporaneously Compounded Oral Liquid Preparations
Yamreudeewong Weeranuj
, Dolence Eric Kurt, Teixeira M Glaucia
Sep/Oct 2011
Pg. 435-437

Book Review: The NMDA Receptor
Jones Marty
Jan/Feb 2000
Pg. 26-27

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain
Mishkan Emilyn S
Sep/Oct 2005
Pg. 339-346

The Treatment of Canine Atopic Disease
Davidson Gigi S
May/Jun 2002
Pg. 210-215

Estrogen Replacement Therapy in the Treatment of Alzheimer's Disease
Osburn Jennifer
May/Jun 2002
Pg. 171-176

Memantine Hydrochloride Capsules
Allen Loyd V Jr
Nov/Dec 2015
Pg. 511

Treating Canine Hepatic Disease
Davidson Gigi S
May/Jun 2003
Pg. 188-191

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions